Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 210543, held by Chartwell Rx. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 210543 (Hydroxychloroquine Sulfate), held by Chartwell Rx, was first approved by FDA on Jul 6, 2018, with 3 approved supplements and 0 published complete response letters.
Hydroxychloroquine sulfate is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. Treatment of rheumatoid arthritis in adults. Treatment of systemic lupus erythematosus in adults. Treatment of chronic discoid lupus erythematosus in adults. Limitations of Use: Hydroxychloroquine sulfate is not recommended for the: Treatment of complicated malaria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 6, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Jun 13, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 7, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 7, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 6, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters